Hyperkalemia | Treatment Algorithms: Claims Data Analysis | US | 2024
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the management of hyperkalemia remains elusive. The aggressiveness of therapy depends on the rapidity with which hyperkalemia develops and absolute K+ concentration. Clinicians address this condition using two primary strategies: intracellular shift of potassium ions (using IV insulin / glucose or inhaled salbutamol) and promoting potassium excretion (via K+ binders and diuretics). In this report, we delve into the key therapeutic approaches and their application in treating newly diagnosed and recently treated hyperkalemia patients.
Questions answered
- What patient shares do key therapies and brands garner by the line of therapy in newly diagnosed hyperkalemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hyperkalemia patients?
- How have K+ binders (Lokelma, and Veltassa) been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of hyperkalemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of hyperkalemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AstraZeneca, Vifor Pharma
Key drugs: Lokelma, Veltassa
KEY FEATURE
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
